CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on January 9, 2001

Name: C. Fong

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gary D. GLICK, et al.

Application Serial No. 09/700,101

Filed: November 8, 2000

THERAPEUTIC APPLICATIONS

OF PRO-APOPTOTIC BENZODIAZEPINES

Art Unit: Unassigned

Examiner: Unassigned

Attorney's Docket No. 128019-203801

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

For:

Listed on accompanying Supplemental Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Supplemental PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted

herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- 1. This Supplemental Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - □ a. I hereby state that each item of information contained in this Information

 Disclosure Statement was cited in a communication from a foreign patent office

 in a counterpart foreign application not more than three months prior to the

 filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - □ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
 - □ c. Attached is our Check No. _____ in the amount of \$ ____ in payment of the fee under 37 C.F.R. § 1.17(p).
 - □ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered. Attached is our Check No. ______ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i).
 - □ a. I hereby state that each item of information contained in this Information

 Disclosure Statement was cited in a communication from a foreign patent office

 in a counterpart foreign application not more than three months prior to the

 filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - ☐ b. I hereby state that no item of information in this Information Disclosure

 Statement was cited in a communication from a foreign patent office in a

counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

	37 C.F.R. § 1.97(e)(2).
□ 4.	Relevance of the non-English language document(s) is discussed in the present
□ 5.	specification.
□ 6.	The document(s) was/were cited in a corresponding to the foreign search report is attached for the Examiner's information. language version of the foreign search report is attached for the Examiner's information. A concise explanation of the relevance of the non-English language document(s)
□ 7.	appears below: The Examiner's attention is directed to co-pending U.S. Patent Application No.
	identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the
□ 8.	art cited therein during examination. Copies of the documents were cited by or submitted to the Office in Application No.
PTC	11 is respectfully requested that the 0-1449, and to indicate in the official file wrapper of this patent application that the
	The U.S. Patent and Trademark Office is hereby authorized to charge any fee sciency, or credit any overpayment, to our Deposit Account No. 50-0974.
	Respectfully submitted,

Date: January 9, 2001

Baker & McKenzie 660 Hansen Way Palo Alto, California 94304 (650) 856-2400 Antoinette F. Konski (Reg. No. 34,202)

PTO/SB/08 (2/92) Sheet 1 of 1

JAN 1 6 2001

Attorney's Docket No. 128019-203801 Supplemental Form PTO-1449 Applicant(s) INFORMATION DISCLOSURE STATEMENT

Application Serial No. 09/700,101

Gary D. GLICK, et al.

Filing Date: November 8, 2000

Group Art Unit: Unassigned

Class Subclass Filing Date Document No. Name Class Subclass Filing Date (if appropriate)					Filing Date: Nov	Citingi o, 2000		•			
Ref. Date Document No. Name Class Subclass Filing Date (if appropriate)	(use sev	eral sheets i	f necessary)	UNG DATENT DOCU	MENTS					
FOREIGN PATENT DOCUMENTS Translation T			1.44		(00) 1 1 1 1 1 1 1 -	Cla	ass	Subclass			
FOREIGN PATENT DOCUMENTS Ref. No. Name Class Subclass Translation YES No. No. No. Name Na		1	Date	Document No.	Name				(if appropr	iate)	
Ref. No. 10/01/1990 0 349 949 A2 EPO	11111111					OUNTAIN					
Examiner No. Date Document No. Name YES No. No. 10/01/1990 0 349 949 A2 EPO Title (Initials No. 10/01/1990 Document No. Name					<u>OREIGN PATENT DU</u>	CUMENTS	255	Subclass	Transla	ation	
1. 10/01/1990 0 349 949 A2 EPO OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Examiner Ref. Initials No. Blum, P., et al., "Stiff-Person Syndrome: An Autoimmune Disease," Movement Disorders – 6(1):12-20 (1991) 2. Blum, P., et al., "B-Carbolines Induce Apoptotic Death of Cerebellar Granule Neurones in Cultures," NeuroRepoil – 7(18):3041-3045 (1996) 4. Miller, K.A., et al., "Benzodiazepines Prevent Neuronal Death by Apoptosis & Necrosis in the Gerbil Hippocampus Following Transient Cerebral Ischemia," Society for Neuroscience Abstracts – 24(1-2):979 (1998) Schlumpf, M., et al., "Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines," Toxic. In Vitro – 3(5):106 (1994) 6. Tanimoto, Y., et al., "Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis Through Reduction of the Mitochondrial Transmembrane Potential," Jpn. J. Pharmacol. – 79:177-183 (1999) Mitochondrial Transmembrane Potential," Jpn. J. Pharmacol. – 79:177-183 (1999) Taupin, V., et al., "Endogenous Anxiogenic peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines Enhance the Production of Interleukin-1 and Tumor Necrosis Factor by Human Monocytes," Lymphokine and Cytokine Reseator Production of Interleukin-1 and Tumor Necrosis Factor by Human Monocytes," Lymphokine and Cytokine Reseator Production of Interleukin-1 and Tumor Necrosis Factor Production Production of Interleukin-1 and Tumor Necrosis Factor Production		1	Date	Document No.	Name				YES	NO	
Common	Illiais		10/01/1990	0 349 949 A2				1			
Initials No. Blum, P., et al., "Stiff-Person Syndrome: An Autoimmune Disease," Movement Disorders – 6(1):12-20 (1991) Malgrange, B., et al., "\$-Carbolines Induce Apoptotic Death of Cerebellar Granule Neurones in Cultures," NeuroReport – 7(18):3041-3045 (1996) 4. Miller, K.A., et al., "Benzodiazepines Prevent Neuronal Death by Apoptosis & Necrosis in the Gerbil Hippocampus Following Transient Cerebral Ischemia,""Society for Neuroscience Abstracts – 24(1-2):979 (1998) 5. Schlumpf, M., et al., "Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines," Toxic. In Vitro – 3(5):106 (1994) 6. Tanimoto, Y., et al., "Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis Through Reduction of the Mitochondrial Transmembrane Potential," Jpn. J. Pharmacol. – 79:177-183 (1999) Mitochondrial Transmembrane Potential," Jpn. J. Pharmacol. – 79:177-183 (1999) Taupin, V., et al., "Endogenous Anxiogenic peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines Enhance the Production of Interleukin-1 and Tumor Necrosis Factor by Human Monocytes," Lymphokine and Cytokine Reseated.		<u> </u>		(includir	OTHER DOCUME og author, title, date, pe	NTS rtinent pages, etc.)					
 Malgrange, B., et al., "B-Carbolines Induce Apoptotic Beath of Death State of Part of Par	Examiner	Ref.	Title						20 (4004)		
 Malgrange, B., et al., "B-Carbolines Induce Apoptotic Beath of Death State of Part of Par	Initials			Lat WOLLE Darean Su	ndrome: An Autoimmu	ine Disease," Movement D	isord	<u>ers – 6(1):12-</u>	20 (1991)	Papart	
 7(18):3041-3045 (1996) Miller, K.A., et al., "Benzodiazepines Prevent Neuronal Death by Apoptosis & Necrosis in the Gerbil Hippocampus Following Transient Cerebral Ischemia," Society for Neuroscience Abstracts – 24(1-2):979 (1998) Schlumpf, M., et al., "Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines," Toxic. In Vitro – 3(5):106 (1994) Tanimoto, Y., et al., "Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis Through Reduction of the Mitochondrial Transmembrane Potential," Jpn. J. Pharmacol. – 79:177-183 (1999) Taupin, V., et al., "Endogenous Anxiogenic peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines Enhance the Production of Interleukin-1 and Tumor Necrosis Factor by Human Monocytes," Lymphokine and Cytokine Reseated 			Blum, P., e	R at al "R Carboli	nes Induce Apoptotic D	eath of Cerebellar Granule	Neu	rones in Cult	ures," Neuro	report	
 Following Transient Cerebral Ischema, Society for Newtonian Schema, Scheman, Scheman,		3.	<u>- 7</u> (18):304	- 7(18):3041-3045 (1996)							
1065 (1994) 6. Tanimoto, Y., et al., "Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis Through Reduction of the Mitochondrial Transmembrane Potential," Jpn. J. Pharmacol. – 79:177-183 (1999) Mitochondrial Transmembrane Potential," Jpn. J. Pharmacol. – 79:177-183 (1999) 7. Taupin, V., et al., "Endogenous Anxiogenic peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines Enhance the Production of Interleukin-1 and Tumor Necrosis Factor by Human Monocytes," Lymphokine and Cytokine Reseated		4.	Miller, K.A., et al., "Benzodiazepines Prevent Neuronal Boats of Prevent Abstracts – 24(1-2):979 (1998) Following Transient Cerebral Ischemia," Society for Neuroscience Abstracts – 24(1-2):979 (1998) Following Transient Cerebral Ischemia, "Society for Neuroscience Abstracts – 24(1-2):979 (1998)								
Mitochondrial Transmembrane Potential, Spin. 3. The Mitochondrial Transmembrane Potential Transmembran		5.	Schlumpf, M., et al., "Delayed Developmental infinitionotoxicity of Frontier and Infinitionotoxicity o								
the Production of Interleukin-1 and Tulkion Necrosia Passara,		6.	Mitochondrial Transmembrane Potential, Spir. 5. 7 Mathitage and Reprodiazenines Enhance								
		7.	the Produ	ction of Interleukin-1	and Tumor Necrosis F	actor by Human Monocyte	s," <i>L</i>)	mphokine al	nd Cytokine	Research	

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conforma not considered. Include a copy of this form with next communication to applicant.

154157.1

194749v1

JAN 1 6 2001

Supplemental Form PTO-1449

Attorney's Docket No. 128019-203801

Application Serial No. 09/700,101

Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Filing Date: November 8, 2000

Gary D. GLICK, et al.

Group Art Unit: Unassigned

(use several sheets if necessary)

		7 07 47 0770000	necessary)								
				U.S. PATENT DOCUMENTS	Class	Subclass	Filing Date	Katalan daring			
xaminer nitials	Ref. No.	Date	Document No.	Name	Class	Subciass	(if appropri	ate)			
			F	OREIGN PATENT DOCUMENTS		Lati	Transla	4!			
xaminer nitials	Ref.	Date	Document No.	Name	Class	Subclass	YES	NO			
	1.	10/01/1990	0 349 949 A2	EPO							
			(includin	OTHER DOCUMENTS ag author, title, date, pertinent pages	s, etc.)						
xaminer	Ref.	Title	_								
nitials	No.	Diseases " Movement Diseases - 6(1):12-20 (1991)									
	2.	Blum, P., et	Blum, P., et al., "Stiff-Person Syndrome: An Autoimmune Disease," Movement Disorders – 6(1):12-20 (1991)								
	3.	Malgrange, B., et al., "Stirr-Person Syndrome: All Autominiums bisease, increased in Cultures," NeuroReport — 7(18):3041-3045 (1996)									
	4.	Miller, K.A., et al., "Benzodiazepines Prevent Neuronal Death by Apoptosis & Necrosis in the Gerbil Hippocampus Following Transient Cerebral Ischemia," Society for Neuroscience Abstracts – 24(1-2):979 (1998)									
	5.	Schlumpf, M., et al., "Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines," Toxic. III Vitio = g(s): 100									
	6.	Tanimoto, Y., et al., "Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis 1 nrough Reduction of the									
	7.	Taupin, V., et al., "Endogenous Anxiogenic peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines Enhance the Production of Interleukin-1 and Tumor Necrosis Factor by Human Monocytes," <i>Lymphokine and Cytokine Research</i> – 10(1):7-13 (1991)									
		<u> </u>					310				
							50				
						PATE	1 6 2001	}			
						· (P)	EMARY				
						TAL	/EMAYS				

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conforma not considered. Include a copy of this form with next communication to applicant.

154157.1

194749v1